Allergy pill tested to protect heart attack survivors
NCT ID NCT07381803
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether fexofenadine, a common allergy medication, can reduce the risk of serious heart and brain events in people who have recently had a heart attack. About 2,800 participants will receive either fexofenadine or a placebo for 24 months. The goal is to see if the drug lowers the chance of death, another heart attack, stroke, or heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fexofenadine hydrochloride (allergy medication)
What this could lead to
If it works, this could point toward a simple, low-cost way to reduce the risk of further heart problems after a heart attack.
What could go wrong
This is a large phase 3 trial, but fexofenadine is not typically used for heart conditions, so it may not provide any benefit. The study is still recruiting, so results are years away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZHEJIANG UNIVERSITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Zhejiang University, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••